Core Viewpoint - Innosera ApS has increased its cash offer for Bavarian Nordic A/S to DKK 250 per share and extended the offer period until November 5, 2025, allowing shareholders more time to consider the offer [3][4][10]. Offer Details - The initial offer price was raised from DKK 233 to DKK 250 per share, which is stated to be the best and final offer price [3][5]. - The offer period has been extended by three weeks, now set to expire on November 5, 2025, at 5:00 p.m. (CET) [2][10]. Shareholder Response - Institutional shareholders representing approximately 5.3% of Bavarian Nordic's share capital have committed to accept the improved offer during the extended period [4]. - As of the latest update, approximately 25.7% of Bavarian Nordic's share capital has accepted the offer, indicating that the minimum acceptance condition has not yet been met [7]. Regulatory and Approval Status - The Offeror has obtained all necessary regulatory approvals for the completion of the offer, with the expectation that proceeds may be paid to shareholders by early December 2025, subject to conditions being met [6][10]. Important Dates - The updated timetable includes key dates such as the announcement of the preliminary result on November 6, 2025, and the expected settlement date for the offer price on December 3, 2025 [10][11].

Core Viewpoint - Innosera ApS, controlled by Nordic Capital Fund XI and Permira, has made a public takeover offer for Bavarian Nordic A/S, with the offer period expiring on 14 October 2025 at 11:59 p.m. (CEST) [1][2]. Group 1: Offer Details - The takeover offer is an all-cash voluntary board-recommended public offer to acquire all issued and outstanding shares of Bavarian Nordic, excluding treasury shares [1]. - The Offeror has received all necessary regulatory approvals, but the completion of the offer is contingent upon meeting a minimum acceptance condition of 75% of shares [2]. - Shareholders must submit their acceptance through their custodian bank or account holding institution before the offer period expires [3]. Group 2: Shareholder Guidance - Shareholders are encouraged to read the Offer Document and the Board Statement in full before deciding whether to accept the offer [4]. - Acceptance can be made online via the custodian bank's web banking solution or by using the acceptance form provided in the Offer Document [3]. Group 3: Company Background - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines [6].

Core Insights - Bavarian Nordic A/S reported topline results from a clinical study of its MVA-BN mpox/smallpox vaccine in children aged 2 to 11 years, indicating a strong immune response and safety profile comparable to adults [1][3][9] Study Details - The clinical study (NCT06549530) enrolled 460 individuals, including children aged 2-11 years and adults aged 18-50 years, to compare the safety and immunogenicity of two standard doses of the MVA-BN vaccine [2] - The study was co-funded by the Coalition for Epidemic Preparedness Innovations (CEPI) and conducted in the Democratic Republic of Congo and Uganda [2] Results Summary - Among 451 evaluable individuals, the immune response in children (n=227) two weeks post-vaccination was non-inferior to that of adults (n=224), with the highest immune responses in the youngest subgroup (2-5 years) [3] - The immune response in children was 2.5 times higher than in adults, as shown by neutralizing antibody titers, and the vaccine was well tolerated with a safety profile similar to that of adults [3] Future Plans - Bavarian Nordic plans to submit the study data to the European Medicines Agency (EMA) in 2026 to seek approval for the vaccine's use in children aged 2 years and older [4] - Currently, MVA-BN is approved for individuals aged 12 years and older in the European Commission [4] Public Health Implications - The findings could expand the vaccine's use in children in countries severely affected by the ongoing mpox outbreak, particularly in Africa [5] - The CEO of Bavarian Nordic emphasized the importance of the vaccine in protecting vulnerable populations, including younger children, against mpox [6] Vaccine Background - MVA-BN is the only non-replicating mpox vaccine approved in several countries, including the U.S. and EU, originally developed as a smallpox vaccine [7] - The vaccine is indicated for use in the general population from 12 years old, particularly for those at risk of smallpox or mpox infection [7] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines and is a preferred supplier of mpox and smallpox vaccines to governments [8]

Takeover Bid - Nordic Capital and Permira extended the offer period for Bavarian Nordic A/S takeover bid [1] - The offer price remains unchanged despite investor opposition to the valuation [1] Valuation Concerns - Key investors are pushing back against the valuation of the Danish vaccine maker [1]

Core Points - Bavarian Nordic A/S has increased its share capital by DKK 3,818,710 due to the exercise of employee warrants [1] - The capital increase was executed without pre-emption rights for existing shareholders, resulting in total proceeds of DKK 78.7 million [2] - The new shares will be listed on Nasdaq Copenhagen and will have the same rights as existing shares, bringing the total nominal value of share capital to DKK 792,367,280 [3] - The announcement does not alter the company's financial expectations for 2025 [4] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines [5]

Core Insights - Bavarian Nordic A/S completed the sale of its Priority Review Voucher (PRV) for a cash consideration of USD 160 million [1] - The net proceeds from the sale, after deducting royalties and transaction costs, amount to DKK 810 million, which will be recognized as other operating income [2] - The company's revenue expectations for 2025 remain unchanged, with a guided EBITDA margin of 26-30% for regular business, while the total EBITDA margin is expected to be in the range of 40-42% when including the extraordinary income from the PRV sale [2][3] Financial Guidance for 2025 - Revenue guidance is set between DKK 5,700 million and DKK 6,700 million [3] - Public Preparedness revenue is expected to be between DKK 3,000 million and DKK 4,000 million [3] - Travel Health revenue is projected at DKK 2,500 million [3] - Other income is estimated at DKK 200 million [3] - The EBITDA margin for regular business is guided at 26% to 30% [3] - Other net operating income from the PRV sale is DKK 810 million [3] - The total EBITDA margin, including extraordinary income, is expected to be between 40% and 42% [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health and saving lives through innovative vaccines [4] - The company is a preferred supplier of mpox and smallpox vaccines to governments, enhancing public health preparedness [4] - Bavarian Nordic also has a leading portfolio of travel vaccines [4]

Group 1 - Bavarian Nordic A/S is in discussions with a consortium consisting of Nordic Capital and Permira regarding a potential takeover offer [1][2] - There is no certainty whether any offer will be made, nor the timing or terms of such an offer [2] - Bavarian Nordic A/S is a global vaccine company focused on improving health through innovative vaccines, including mpox and smallpox vaccines [3]

Core Insights - Bavarian Nordic A/S has received an additional contract option from BARDA valued at USD 143.6 million for the supply of freeze-dried JYNNEOS smallpox vaccine [1][10] - The new contract options will support the manufacturing and supply of the freeze-dried formulation, which has an extended shelf life, with deliveries planned for 2026 [2][8] Financial Guidance - Bavarian Nordic's financial guidance for 2025 remains unchanged, projecting total revenues between DKK 5,700 million and DKK 6,700 million, with an EBITDA margin of 26-30% [3] - Revenue from the Public Preparedness business is expected to be between DKK 3,000 million and DKK 4,000 million, with DKK 2,650 million already secured, reflecting an increase of DKK 150 million due to the exercise of the options [3] Product Development and Approval - The freeze-dried formulation of JYNNEOS was approved by the FDA in March 2025, offering advantages in transportation, storage, and shelf life compared to the liquid-frozen version [8] - JYNNEOS is the first smallpox vaccine developed under Project BioShield, which aims to enhance the availability of medical countermeasures against various threats [6] Historical Context - Bavarian Nordic has been collaborating with the U.S. government since 2003 for the development and supply of smallpox vaccines, including the liquid-frozen formulation supplied since 2010 [5][7] - The company has a ten-year contract awarded in 2017, which includes options valued at USD 299 million for the fill and finish of freeze-dried vaccines, of which USD 284 million has been exercised to date [7]

Core Viewpoint - Bavarian Nordic A/S has received marketing authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its chikungunya vaccine, VIMKUNYA, aimed at individuals aged 12 and older, with a planned launch in the UK during the summer of 2025 [1][2][3]. Group 1: Vaccine Approval and Launch - The approval of VIMKUNYA follows a review under the international recognition procedure, acknowledging prior approvals from other regulatory bodies, including the European Commission [2]. - This marks the third approval for Bavarian Nordic's chikungunya vaccine, following approvals from the U.S. FDA and the European Commission in February 2025 [3]. Group 2: Disease Background - Chikungunya is a mosquito-borne disease that has emerged in over 110 countries, with significant outbreaks reported in Asia, Africa, and the Americas [4]. - In 2024, there were 620,000 reported cases of chikungunya globally, resulting in over 200 deaths, indicating a potential underreporting of the disease [4]. Group 3: Vaccine Details and Efficacy - VIMKUNYA is a single-dose, adjuvanted VLP recombinant protein vaccine designed for active immunization against chikungunya virus [5]. - Phase 3 clinical trials involving over 3,500 participants demonstrated that 21 days post-vaccination, up to 97.8% of individuals developed neutralizing antibodies [6]. Group 4: Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, with a strong portfolio in travel vaccines and public health preparedness [7].